Buy JNJ: A Durable, Income-Producing Anchor to Balance an AI-Heavy Portfolio
Johnson & Johnson ($JNJ) is a large-cap defensive compounder with a diversified MedTech and Innovative Medicine franchise, $17.4B in free cash flow, and a 2.3% yield. Recent positive Phase 3 data on TALVEY and continued margin resilience make JNJ an attractive buy to balance AI/concentrated-tech exposure. Initiate Buy with entry $228.40, target $26…